Literature DB >> 28353089

Histological, immunohistological and molecular characteristics of intraductal precursor of carcinoma ex pleomorphic adenoma support a multistep carcinogenic process.

Stephan Ihrler1,2, Orlando Guntinas-Lichius3, Abbas Agaimy4, Agnes Wolf5, Martin Mollenhauer6.   

Abstract

In recent years, multistep carcinogenesis of carcinoma ex pleomorphic adenoma (CEPA) has been identified, starting with intraductal neoplasia within pre-existent pleomorphic adenoma (PA). However, as yet there is no consensus regarding clinical relevance and appropriate terminology of precursor lesions in CEPA. We therefore decided to investigate precursor lesions, especially intraductal carcinoma, in a series of 85 cases of CEPA. Intraductal carcinoma confined by benign myoepithelial cells was found in 60 cases and mostly exhibited high-grade cellular atypia, increased cellular proliferation and frequent genetic alterations (TP53, Her2-neu, androgen receptor). Intraductal carcinoma was absent only in the myoepithelial type of CEPA. In 26 cases, purely intraductal CEPA with extensive intraductal expansion was found. This suggests that there is a long period of intraductal growth before extraductal intracapsular infiltration of the PA. We identified two different histomorphological types of intraductal carcinoma, which we call 'clinging' and 'solid' types. In summary, combined histological, immunohistological and molecular data strongly support multistep carcinogenesis starting with intraductal carcinoma for all non-myoepithelial types of CEPA. The clinical significance of our finding of two histomorphological types of intraductal carcinoma (clinging and solid) is not yet clear. Intraductal carcinoma, intracapsular invasive CEPA and minor extracapsular invasive CEPA (up to about 6 mm) all show favourable prognosis and together comprise half of the cases in our study.

Entities:  

Keywords:  Carcinogenesis; Carcinoma ex pleomorphic adenoma; Intracapsular carcinoma; Intraductal carcinoma; Salivary gland carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28353089     DOI: 10.1007/s00428-017-2106-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  29 in total

1.  Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases.

Authors:  Christoph Weiler; Pamela Zengel; Jacqueline E van der Wal; Orlando Guntinas-Lichius; Stephan Schwarz; John D Harrison; Thomas Kirchner; Stephan Ihrler
Journal:  Histopathology       Date:  2011-10       Impact factor: 5.087

2.  Molecular genetic alterations in carcinoma ex-pleomorphic adenoma: a putative progression model?

Authors:  A K El-Naggar; D Callender; M M Coombes; K Hurr; M A Luna; J G Batsakis
Journal:  Genes Chromosomes Cancer       Date:  2000-02       Impact factor: 5.006

3.  Atypical features in salivary gland mixed tumors: their relationship to malignant transformation.

Authors:  P L Auclair; G L Ellis
Journal:  Mod Pathol       Date:  1996-06       Impact factor: 7.842

4.  Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases.

Authors:  Nora Katabi; Daniel Gomez; David S Klimstra; Diane L Carlson; Nancy Lee; Ronald Ghossein
Journal:  Hum Pathol       Date:  2010-03-24       Impact factor: 3.466

5.  Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.

Authors:  Silvana Di Palma; Roderick H W Simpson; Caterina Marchiò; Alena Skálová; Marco Ungari; Ann Sandison; Stephen Whitaker; Suzanne Parry; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2012-10       Impact factor: 5.087

6.  Noninvasive and minimally invasive carcinoma ex mixed tumor: a clinicopathologic and ploidy study of 12 patients with major salivary tumors of low (or no?) malignant potential.

Authors:  M Brandwein; A G Huvos; I Dardick; M J Thomas; N D Theise
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1996-06

7.  The role of the p53 gene in the malignant transformation of pleomorphic adenomas of the parotid gland.

Authors:  P D Righi; Y Q Li; M Deutsch; J S McDonald; K M Wilson; P Bejarano; P J Stambrook; D Osterhage; C Nguyen; J L Gluckman
Journal:  Anticancer Res       Date:  1994 Sep-Oct       Impact factor: 2.480

8.  An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions.

Authors:  Armita Bahrami; Bayardo Perez-Ordonez; James D Dalton; Ilan Weinreb
Journal:  Histopathology       Date:  2013-06-06       Impact factor: 5.087

9.  Immunohistochemical evaluation of androgen receptor, HER-2/neu, and p53 in benign pleomorphic adenomas.

Authors:  Tom C DeRoche; Aaron P Hoschar; Jennifer L Hunt
Journal:  Arch Pathol Lab Med       Date:  2008-12       Impact factor: 5.534

10.  Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry.

Authors:  A Skálová; I Stárek; T Vanecek; V Kucerová; L Plank; P Szépe; S Di Palma; I Leivo
Journal:  Histopathology       Date:  2003-04       Impact factor: 5.087

View more
  3 in total

Review 1.  [Updates on tumours of the salivary glands : 2017 WHO classification].

Authors:  S Ihrler; O Guntinas-Lichius; C Haas; M Mollenhauer
Journal:  Pathologe       Date:  2018-02       Impact factor: 1.011

Review 2.  Development of head and neck pathology in Europe.

Authors:  Henrik Hellquist; Abbas Agaimy; Göran Stenman; Alessandro Franchi; Alfons Nadal; Alena Skalova; Ilmo Leivo; Nina Zidar; Roderick H W Simpson; Pieter J Slootweg; Juan C Hernandez-Prera; Alfio Ferlito
Journal:  Virchows Arch       Date:  2022-01-14       Impact factor: 4.064

3.  Malignant transformation of salivary gland pleomorphic adenoma: proof of principle.

Authors:  Matthijs H Valstar; Hetty Mast; Ivo Ten Hove; Laura R Moonen; Alfons Jm Balm; Ludi E Smeele; Senada Koljenović; Winand Nm Dinjens; Marie-Louise F van Velthuysen
Journal:  J Pathol Clin Res       Date:  2021-05-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.